High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: Results of a randomised study

British Journal of Haematology

Volumn 130, Issue 4, 2005, Pages 588-594

  Fenk, R ^a   Schneider, P ^a   Kropff, M ^b   Huenerlituerkoglu, A N ^b   Steidl, U ^a   Aul, C ^a   Hildebrandt, B ^a   Haas, R ^a   Heyll, A ^a   Kobbe, G ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Autologous transplantation; High dose therapy; Multiple myeloma; Randomised trial

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IBANDRONIC ACID; IDARUBICIN; MELPHALAN; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE TOXICITY; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEPSIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; REMISSION; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IDARUBICIN; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 24944562841     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05641.x     Document Type: Article

References (18)

1. Abraham R. Chen C. Tsang R. Simpson D. Murray C. Davidson M. Meharchand J. Sutton D.M. Crump R.M. Keating A. Stewart A.K. ( 1999) Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma. Bone Marrow Transplantation, 24, 1291 1297.
2. Alexanian R. Weber D. Giralt S. Dimopoulos M. Delasalle K. Smith T. Champlin R. ( 2001) Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplantation, 27, 1037 1043.
3. Attal M. Harousseau J.L. Stoppa A.M. Sotto J.J. Fuzibet J.G. Rossi J.F. Casassus P. Maisonneuve H. Facon T. Ifrah N. Payen C. Bataille R. ( 1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 91 97.
4. Blade J. Vesole D.H. Gertz M. ( 2003) High-dose therapy in multiple myeloma. Blood, 102, 3469 3470.
5. Child J.A. Morgan G.J. Davies F.E. Owen R.G. Bell S.E. Hawkins K. Brown J. Drayson M.T. Selby P.J. ( 2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 1875 1883.
6. Cook G. Clark R.E. Morris T.C. Robertson M. Lucie N.P. Anderson S. Paul J. Franklin I.M. ( 2004) A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. British Journal of Haematology, 126, 792 798.
7. Davies F.E. Forsyth P.D. Rawstron A.C. Owen R.G. Pratt G. Evans P.A. Richards S.J. Drayson M. Smith G.M. Selby P.J. Child J.A. Morgan G.J. ( 2001) The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. British Journal of Haematology, 112, 814 819.
8. De Witte T. Suciu S. Selleslag D. Labar B. Roozendaal K. Zittoun R. Ribeiro M. Kurstjens R. Hayat M. Dardenne M. Solbu G. Muus P. ( 1996) Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group. Annals of Hematology, 72, 119 124.
9. Einsele H. Bamberg M. Budach W. Schmidberger H. Hess C.F. Wormann B. Meisner C. Straka C. Hebart H. Trumper L. Kroger N. Zander A.R. Hegewisch-Becker S. Hossfeld D.K. Schmidt H. Muller P. Schlimok G. Hertenstein B. Peest D. Metzner B. Frickhofen N. Kanz L. Bensinger W.I. ( 2003) A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplantation, 32, 593 599.
10. Glasmacher A. Goldschmidt H. Mezger J. Haferlach T. Schmidt-Wolf I.G. Gieseler F. ( 2004) Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial. Haematologica, 89, 371 373.
11. Heyll A. Sohngen D. Kobbe G. Schneider P. Bauser U. Thiele K.P. Wehmeier A. Sudhoff T. Quenzel E.M. Rieth C. Wernet P. Fischer J. Frick M. Aul C. ( 1997) Idarubicin, melphalan and cyclophosphamide: an intensified high-dose regimen for the treatment of myeloma patients. Leukemia, 11 ( Suppl. 5 S32 S34.
12. Jerjis S. Roovers E. Muus P. Schaap N. De Witte T. ( 1998) Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Bone Marrow Transplantation, 22, 13 19.
13. Lahuerta J.J. Martinez-Lopez J. Serna J.D. Blade J. Grande C. Alegre A. Vazquez L. Garcia-Larana J. Sureda A. Rubia J.D. Conde E. Martinez R. Perez-Equiza K. Moraleda J.M. Leon A. Besalduch J. Cabrera R. Miguel J.D. Morales A. Garcia-Ruiz J.C. Diaz-Mediavilla J. San Miguel J. ( 2000) Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. British Journal of Haematology, 109, 438 446.
14. Martinelli G. Agazzi A. Laszlo D. Santoro P. Mancuso P. Pruneri G.C. Greco P. Bertolini F. ( 2003) Idarubicin containing regimen in multiple myeloma: preliminary results of a pilot study using a modified ''TANDEM" transplant program. Leukemia and Lymphoma, 44, 299 302.
15. Meloni G. Capria S. Trasarti S. Ferrazza G. Micozzi A. Petrucci M.T. Simone F. Trisolini S.M. Mandelli F. ( 2000) High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study. Bone Marrow Transplantation, 26, 1045 1049.
16. Muus P. Donnelly P. Schattenberg A. Linssen P. Minderman H. Dompeling E. De Witte T. ( 1993) Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. Seminars in Oncology, 20, 47 52.
17. Nadal E. Gine E. Blade J. Esteve J. Rosinol L. Fernandez-Aviles F. Marin P. Martinez C. Rovira M. Urbano-Ispizua A. Carreras E. Montserrat E. ( 2004) High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplantation, 33, 61 64.
18. Ria R. Falzetti F. Ballanti S. Minelli O. Di Ianni M. Cimminiello M. Vacca A. Dammacco F. Martelli M.F. Tabilio A. ( 2004) Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. The Hematology Journal, 5, 118 122.